The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
 
Julie Lemieux
No Relationships to Disclose
 
Paul E. Goss
No Relationships to Disclose
 
Wendy R. Parulekar
No Relationships to Disclose
 
James N. Ingle
No Relationships to Disclose
 
Kathleen I. Pritchard
Honoraria - Amgen; AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
 
Nicholas J. Robert
Consulting or Advisory Role - New Century Health
Research Funding - Side-Out Foundation
Other Relationship - Paradigm
 
Hyman Muss
Consulting or Advisory Role - Pfizer
 
Julie Gralow
Consulting or Advisory Role - Bayer; Genentech; Lilly; Novartis
Research Funding - Amgen (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Kathrin Strasser-Weippl
Consulting or Advisory Role - Celgene; Roche
Travel, Accommodations, Expenses - Merck; Roche
 
Michael Donald Brundage
No Relationships to Disclose
 
Kate Whelan
No Relationships to Disclose
 
Dongsheng Tu
No Relationships to Disclose
 
Timothy Joseph Whelan
No Relationships to Disclose